JP2022547168A5 - - Google Patents
Info
- Publication number
- JP2022547168A5 JP2022547168A5 JP2022515493A JP2022515493A JP2022547168A5 JP 2022547168 A5 JP2022547168 A5 JP 2022547168A5 JP 2022515493 A JP2022515493 A JP 2022515493A JP 2022515493 A JP2022515493 A JP 2022515493A JP 2022547168 A5 JP2022547168 A5 JP 2022547168A5
- Authority
- JP
- Japan
- Prior art keywords
- casx
- gna
- sequence
- protein
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962897947P | 2019-09-09 | 2019-09-09 | |
| US62/897,947 | 2019-09-09 | ||
| US202063075041P | 2020-09-04 | 2020-09-04 | |
| US63/075,041 | 2020-09-04 | ||
| PCT/US2020/050008 WO2021050601A1 (en) | 2019-09-09 | 2020-09-09 | Compositions and methods for use in immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022547168A JP2022547168A (ja) | 2022-11-10 |
| JP2022547168A5 true JP2022547168A5 (enExample) | 2023-09-15 |
| JP7696335B2 JP7696335B2 (ja) | 2025-06-20 |
Family
ID=72644925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515493A Active JP7696335B2 (ja) | 2019-09-09 | 2020-09-09 | 免疫療法に使用するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12551560B2 (enExample) |
| EP (1) | EP4028523A1 (enExample) |
| JP (1) | JP7696335B2 (enExample) |
| KR (1) | KR20220070456A (enExample) |
| CN (1) | CN114729368A (enExample) |
| AU (1) | AU2020344553A1 (enExample) |
| CA (1) | CA3153700A1 (enExample) |
| IL (1) | IL291176A (enExample) |
| WO (1) | WO2021050601A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP3980533A1 (en) | 2019-06-07 | 2022-04-13 | Scribe Therapeutics Inc. | Engineered casx systems |
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| WO2021050601A1 (en) | 2019-09-09 | 2021-03-18 | Scribe Therapeutics Inc. | Compositions and methods for use in immunotherapy |
| IL294620A (en) * | 2020-01-10 | 2022-09-01 | Scribe Therapeutics Inc | Compositions and methods for the targeting of pcsk9 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| CA3189601A1 (en) | 2020-07-24 | 2022-01-27 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| KR20230128289A (ko) | 2020-12-03 | 2023-09-04 | 스크라이브 테라퓨틱스 인크. | 조작된 클래스 2 유형 v crispr 시스템 |
| US12171813B2 (en) | 2021-02-05 | 2024-12-24 | Christiana Care Gene Editing Institute, Inc. | Methods of and compositions for reducing gene expression and/or activity |
| CN113151470A (zh) * | 2021-04-26 | 2021-07-23 | 暨南大学 | 多基因联合在制备预测aml预后试剂盒中的应用 |
| US20260009009A1 (en) * | 2021-05-06 | 2026-01-08 | Celyntra Therapeutics Sa | Modified nucleases |
| CN113209019B (zh) * | 2021-05-11 | 2022-03-15 | 西北工业大学 | Nk细胞协同刺激聚合物胶束的制备方法及应用 |
| WO2022242701A1 (en) * | 2021-05-20 | 2022-11-24 | Wuxi Biologics (Shanghai) Co., Ltd. | Genetically modified gamma-delta t cells and uses thereof |
| WO2022261149A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| CN114164234A (zh) * | 2021-11-30 | 2022-03-11 | 东莞市麦亘生物科技有限公司 | 利用CRISPR/Cas9技术构建可靶向MSLN新型CAR-T细胞的方法 |
| WO2023167752A2 (en) * | 2021-12-09 | 2023-09-07 | The Broad Institute, Inc. | Small novel crispr-cas systems and methods of use thereof |
| CN118742571A (zh) * | 2022-02-09 | 2024-10-01 | 恺兴生命科技(上海)有限公司 | 用于细胞免疫学的组合物和方法 |
| WO2023235818A2 (en) * | 2022-06-02 | 2023-12-07 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| WO2023235888A2 (en) | 2022-06-03 | 2023-12-07 | Scribe Therapeutics Inc. | COMPOSITIONS AND METHODS FOR CpG DEPLETION |
| WO2023240027A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Particle delivery systems |
| TW202413643A (zh) | 2022-06-07 | 2024-04-01 | 美商斯奎柏治療公司 | 用於靶向pcsk9的組合物及方法 |
| GB2634837A (en) | 2022-06-07 | 2025-04-23 | Scribe Therapeutics Inc | Compositions and methods for the targeting of PCSK9 |
| US20250361525A1 (en) | 2022-06-08 | 2025-11-27 | Scribe Therapeutics Inc. | Aav vectors for gene editing |
| AU2023347891A1 (en) * | 2022-09-19 | 2025-04-10 | Emendobio Inc. | Biallelic knockout of ciita |
| WO2024097800A1 (en) * | 2022-11-01 | 2024-05-10 | Fate Therapeutics, Inc. | Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting kallikrein-2 |
| WO2024127370A1 (en) * | 2022-12-16 | 2024-06-20 | LifeEDIT Therapeutics, Inc. | Guide rnas that target trac gene and methods of use |
| CN116287090A (zh) * | 2023-02-10 | 2023-06-23 | 同济大学 | 一种检测细胞naïve态多能性的方法及可指征naïve态多能性的双报告系统 |
| AU2024236558A1 (en) | 2023-03-15 | 2025-10-09 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
| CN120366391A (zh) * | 2023-04-18 | 2025-07-25 | 上海本导基因技术有限公司 | 一种用于治疗亨廷顿疾病的慢病毒样颗粒 |
| EP4705456A1 (en) * | 2023-05-05 | 2026-03-11 | Celyntra Therapeutics SA | Compositions and methods for targeting, editing or modifying human genes |
| CN121586777A (zh) * | 2023-07-26 | 2026-02-27 | 上海邦耀生物医药有限公司 | 用于治疗疾病的方法和组合物 |
| CN116732099B (zh) * | 2023-08-07 | 2023-11-24 | 北赛泓升(北京)生物科技有限公司 | 一种干细胞多重CRISPR/Cas基因组编辑方法 |
| AU2024335327A1 (en) | 2023-09-01 | 2026-03-26 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| GB202401412D0 (en) * | 2024-02-02 | 2024-03-20 | Harness Therapeutics Ltd | Functional nucleic acid |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| CN118995709A (zh) * | 2024-08-23 | 2024-11-22 | 东北农业大学 | 一种提高基因编辑效率的重组型pegRNA及其应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5695937A (en) | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US20020131960A1 (en) | 2000-06-02 | 2002-09-19 | Michel Sadelain | Artificial antigen presenting cells and methods of use thereof |
| ATE338124T1 (de) | 2000-11-07 | 2006-09-15 | Hope City | Cd19-spezifische umgezielte immunzellen |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| WO2010075303A1 (en) | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same |
| WO2012068627A1 (en) | 2010-11-24 | 2012-05-31 | The University Of Western Australia | Peptides for the specific binding of rna targets |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| CN104080797A (zh) | 2011-11-11 | 2014-10-01 | 弗雷德哈钦森癌症研究中心 | 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法 |
| CA2861491C (en) | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| EP2844743B1 (en) | 2012-05-03 | 2021-01-13 | Fred Hutchinson Cancer Research Center | Enhanced affinity t cell receptors and methods for making the same |
| BR122020002986A8 (pt) | 2012-08-20 | 2023-04-18 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Método e composições para imunoterapia celular |
| WO2014165707A2 (en) | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| EP3215623A4 (en) | 2014-11-06 | 2018-09-26 | President and Fellows of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
| AU2016323985B2 (en) | 2015-09-17 | 2022-12-15 | Novartis Ag | CAR T cell therapies with enhanced efficacy |
| WO2017068077A1 (en) * | 2015-10-20 | 2017-04-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods and products for genetic engineering |
| WO2017083722A1 (en) | 2015-11-11 | 2017-05-18 | Greenberg Kenneth P | Crispr compositions and methods of using the same for gene therapy |
| WO2017093969A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| AU2017223821B2 (en) | 2016-02-23 | 2023-07-27 | Arc Bio, Llc | Methods and compositions for target detection |
| US20190136230A1 (en) | 2016-05-06 | 2019-05-09 | Juno Therapeutics, Inc. | Genetically engineered cells and methods of making the same |
| AU2017280353B2 (en) | 2016-06-24 | 2021-11-11 | Inscripta, Inc. | Methods for generating barcoded combinatorial libraries |
| MX2019003674A (es) | 2016-09-30 | 2021-01-08 | Univ California | Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas. |
| US9982267B2 (en) | 2016-10-12 | 2018-05-29 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
| CN110291100B (zh) | 2016-10-12 | 2024-06-11 | 费尔丹生物公司 | 用于将多肽负荷从细胞外空间递送至靶真核细胞的胞质溶胶和/或细胞核的合理设计的合成肽穿梭剂，其用途、与其相关的方法和试剂盒 |
| JP2020505025A (ja) | 2017-01-13 | 2020-02-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 免疫工学的な改変をした多能性細胞 |
| US20190367924A1 (en) | 2017-02-17 | 2019-12-05 | Temple University - Of The Commonwealth System Of Higher Education | Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5 |
| WO2018195555A1 (en) | 2017-04-21 | 2018-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors |
| US20200407737A1 (en) * | 2017-05-03 | 2020-12-31 | KWS SAAT SE & Co. KGaA | Use of crispr-cas endonucleases for plant genome engineering |
| MX2019013514A (es) | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| CN109963944A (zh) | 2017-06-20 | 2019-07-02 | 江苏恒瑞医药股份有限公司 | 体外敲除T细胞中靶基因的方法以及该方法中使用的crRNA |
| EP3441461A1 (en) * | 2017-08-11 | 2019-02-13 | Baylor College of Medicine | Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy |
| US11718659B2 (en) | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
| CA3074872A1 (en) * | 2017-09-07 | 2019-03-14 | The Board Of Trustees Of The Leland Stanford Junior University | Nuclease systems for genetic engineering |
| EP3686275A4 (en) | 2017-09-18 | 2021-09-29 | Edigene Inc. | GENE EDITING LYMPHOCYTE T AND RELATED USE |
| US11578334B2 (en) * | 2017-10-25 | 2023-02-14 | Monsanto Technology Llc | Targeted endonuclease activity of the RNA-guided endonuclease CasX in eukaryotes |
| EP3724326A1 (en) * | 2017-12-11 | 2020-10-21 | Editas Medicine, Inc. | Cpf1-related methods and compositions for gene editing |
| EP3746554A1 (en) | 2018-01-30 | 2020-12-09 | Editas Medicine, Inc. | Systems and methods for modulating chromosomal rearrangements |
| US20210284981A1 (en) | 2018-07-24 | 2021-09-16 | The Regents Of The University Of California | Rna-guided nucleic acid modifying enzymes and methods of use thereof |
| US20210324357A1 (en) * | 2018-08-20 | 2021-10-21 | The Brigham And Women's Hospital, Inc. | Degradation domain modifications for spatio-temporal control of rna-guided nucleases |
| US12275964B2 (en) | 2018-08-22 | 2025-04-15 | The Regents Of The University Of California | Variant type V CRISPR/Cas effector polypeptides and methods of use thereof |
| EP3980533A1 (en) | 2019-06-07 | 2022-04-13 | Scribe Therapeutics Inc. | Engineered casx systems |
| WO2021050601A1 (en) | 2019-09-09 | 2021-03-18 | Scribe Therapeutics Inc. | Compositions and methods for use in immunotherapy |
| KR20230128289A (ko) | 2020-12-03 | 2023-09-04 | 스크라이브 테라퓨틱스 인크. | 조작된 클래스 2 유형 v crispr 시스템 |
-
2020
- 2020-09-09 WO PCT/US2020/050008 patent/WO2021050601A1/en not_active Ceased
- 2020-09-09 EP EP20780450.1A patent/EP4028523A1/en active Pending
- 2020-09-09 US US17/641,404 patent/US12551560B2/en active Active
- 2020-09-09 KR KR1020227011467A patent/KR20220070456A/ko active Pending
- 2020-09-09 AU AU2020344553A patent/AU2020344553A1/en active Pending
- 2020-09-09 CN CN202080077031.0A patent/CN114729368A/zh active Pending
- 2020-09-09 JP JP2022515493A patent/JP7696335B2/ja active Active
- 2020-09-09 CA CA3153700A patent/CA3153700A1/en active Pending
-
2022
- 2022-03-07 IL IL291176A patent/IL291176A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022547168A5 (enExample) | ||
| AU2021364314B2 (en) | DNA-containing polynucleotides and guides for CRISPR type V systems, and methods of making and using the same | |
| KR102761346B1 (ko) | 저항원성 세포의 제조 방법 | |
| US20240117383A1 (en) | Selection by essential-gene knock-in | |
| KR20210129105A (ko) | 면역치료법을 위한 변형된 자연 살해(nk) 세포 | |
| JP6752148B2 (ja) | 三官能性ｔ細胞−抗原カプラ及び方法並びにこれらの使用 | |
| US20240293543A1 (en) | Engineered cells for therapy | |
| JP2021522820A5 (enExample) | ||
| EP3532105B1 (en) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogennous foxp3 gene | |
| US20200071773A1 (en) | Tumor signature for metastasis, compositions of matter methods of use thereof | |
| JP2021530999A5 (enExample) | ||
| US20250154503A1 (en) | Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression | |
| JP2021518160A5 (enExample) | ||
| AU2019216269A1 (en) | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen | |
| JP2024506751A5 (enExample) | ||
| CA2937711A1 (en) | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells | |
| WO2018233596A1 (zh) | 体外敲除T细胞中靶基因的方法以及该方法中使用的crRNA | |
| US20240254444A1 (en) | Engineered cells for therapy | |
| CN115485367B (zh) | 用于细胞工程的安全港基因座 | |
| US20250305003A1 (en) | Genome editing of cells | |
| CN116507722A (zh) | 用于crispr v型系统的含有dna的多核苷酸和引导物及制备和使用其的方法 | |
| RU2832314C1 (ru) | Днк-содержащие полинуклеотиды и руководящие последовательности для систем crispr типа v и способы их получения и применения | |
| Scott | The Role of TOX in T Cell Differentiation and Function | |
| Pekarsky | Cloning, characterization and transcriptional mapping of the 3q21 leukemia breakpoint region | |
| Hosler | Characterization of the zinc finger gene Rex-1 (Zfp-42) whose expression is reduced in murine F9 embryonal carcinoma cells treated with retinoic acid |